How to choose pharmacovigilance providers for long-term compliance

Pharmaceutical companies today face a difficult reality. Regulatory expectations are increasing, safety data volumes continue to grow, and health authorities expect continuous oversight of product safety throughout the entire product lifecycle. At the same time, internal teams are often under pressure to do more with fewer resources, making it increasingly challenging to maintain compliance while supporting business growth. Every year, pharmaceutical companies search online for lists of “top pharmacovigilance vendors ranked” in an effort to identify the best outsourcing partner. However, rankings rarely reveal which pharmacovigilance providers are best equipped to support long-term compliance, inspection readiness, and evolving regulatory expectations.

As a result, many organizations begin searching for pharmacovigilance providers that can help manage operational activities and reduce workload. Increasingly, they are also looking for pharmacovigilance consulting support to help navigate complex regulatory requirements, inspection readiness, and long-term compliance challenges. However, this is where a critical mistake often occurs. Companies frequently evaluate pharmacovigilance providers based on size, geographic coverage, or outsourcing capacity, assuming that larger providers automatically offer better support.

The problem is that compliance failures rarely happen because a provider lacks resources. They happen because organizations lack access to the right expertise when complex safety, regulatory, or inspection-related challenges arise. A missed safety signal, incomplete documentation, delayed regulatory response, or inspection finding can lead to significant compliance risks, increased regulatory scrutiny, and costly remediation efforts.

This challenge is becoming even more important as pharmacovigilance expands beyond traditional adverse event management into areas such as environmental risk, radiopharmaceutical safety, and increasingly complex global regulatory requirements. Choosing the wrong partner today can create long-term compliance challenges tomorrow.

For pharmaceutical companies seeking sustainable growth, the question is no longer which provider is the largest. The real question is which pharmacovigilance providers have the expertise, scientific leadership, and regulatory experience needed to support long-term compliance and future business success.

What pharmaceutical companies should evaluate before selecting pharmacovigilance providers

Many pharmaceutical companies realize they need external pharmacovigilance support only after they begin experiencing compliance pressures. Growing safety data volumes, increasing regulatory scrutiny, inspection findings, resource constraints, and expanding global obligations can quickly overwhelm even experienced internal teams.

The challenge is that pharmacovigilance has evolved far beyond adverse event processing. Today, companies must ensure effective signal detection, maintain inspection readiness, manage aggregate reporting, oversee complex vendor networks, respond to regulatory requests, and continuously demonstrate compliance throughout the product lifecycle. At the same time, health authorities expect organizations to identify and address risks proactively rather than reactively.

This creates a difficult situation for many companies. Internal teams are often focused on day-to-day operational activities, leaving limited capacity for strategic oversight, process improvements, and long-term compliance planning. As regulations continue to evolve, organizations that rely on outdated systems, fragmented processes, or insufficient expertise may expose themselves to inspection findings, remediation costs, delayed market activities, and reputational risks.

Before selecting pharmacovigilance providers, pharmaceutical companies should therefore take a step back and evaluate whether their current pharmacovigilance system is truly fit for the future. They should assess the maturity of their safety processes, identify potential compliance gaps, understand resource limitations, and determine where additional expertise is required. Most importantly, they should look beyond operational support and consider whether a provider can help them navigate emerging challenges such as increasingly complex global regulations, evolving safety expectations, environmental considerations, and new therapeutic modalities.

The most successful organizations are not those that wait for compliance issues to emerge. They are the ones that proactively strengthen their pharmacovigilance systems and partner with pharmacovigilance providers capable of supporting sustainable compliance, regulatory confidence, and long-term business growth.

How Billev Pharma East helps companies build long-term pharmacovigilance compliance

Finding the right pharmacovigilance providers is not simply about outsourcing activities. It is about finding a partner capable of strengthening compliance, reducing risk, and supporting business growth in an increasingly complex regulatory environment.

Billev Pharma East provides pharmacovigilance services designed to help pharmaceutical companies move beyond reactive compliance management and build sustainable pharmacovigilance systems that can withstand regulatory scrutiny. Its experts support organizations throughout the entire product lifecycle, helping them identify vulnerabilities before they become inspection findings, compliance gaps, or costly remediation projects.

What makes their approach different is that they combine pharmacovigilance expertise with broader regulatory, quality, toxicology, and market access knowledge. This allows them to look beyond individual pharmacovigilance activities and evaluate how safety processes interact with the wider regulatory landscape. Whether companies require support with QPPV responsibilities, signal management, case processing, aggregate reporting, pharmacovigilance audits, literature monitoring, or inspection readiness, our team provides practical solutions tailored to real-world challenges.

For companies expanding internationally, they also help bridge the gap between local requirements and European regulatory expectations. This is particularly valuable for organizations preparing for EU market entry, where pharmacovigilance obligations can become a significant barrier to successful commercialization if not addressed early. Unlike many pharmacovigilance providers that focus exclusively on operational service delivery,

Most importantly, they do not wait for problems to emerge. Billev Pharma East works proactively with its clients to strengthen processes, improve oversight, reduce compliance risks, and prepare for future regulatory developments. In a landscape where regulations continue to evolve and safety expectations continue to increase, pharmaceutical companies need more than operational support. They need trusted experts who can help them navigate uncertainty with confidence. This is particularly important for organizations evaluating multiple pharmacovigilance vendors, where the key differentiator is often not operational capacity but the ability to provide strategic guidance, regulatory expertise, and long-term compliance support.

That is why companies looking for experienced pharmacovigilance providers increasingly seek partners who can deliver not only services, but also strategic expertise, scientific leadership, and long-term regulatory confidence.

Shaping the future of pharmacovigilance through scientific expertise

The best pharmacovigilance providers do more than manage safety processes and regulatory obligations. They actively contribute to the scientific discussions that shape the future of pharmacovigilance and patient safety. For pharmaceutical companies, this provides an important advantage: access to expertise that goes beyond compliance and keeps pace with emerging regulatory and scientific developments.

At Billev Pharma East, this commitment is reflected through the work of Dr. Jana Brajdih Čendak, Medical and Pharmacovigilance Lead and EU QPPV. Jana combines extensive experience in pharmacovigilance, clinical research, toxicology, and radiopharmaceuticals, helping pharmaceutical companies navigate increasingly complex safety and regulatory challenges.

In 2026, Jana received international recognition through the Best Presentation Award at the XX International Conference on Pharmacovigilance and Drug Safety (ICPDS 2026) in London. The award was presented for her work “Quality of Reports on Drug Toxicity in EudraVigilance: A Safety Physician’s Perspective”, highlighting the importance of high-quality safety data and its impact on regulatory decision-making and patient protection.

Jana’s expertise will also be showcased on the global stage at the ISoP Global Meeting 2026 in Costa Rica, where she will present “The Atomic Ecosystem of Trust: Expanding Radiopharmaceutical Pharmacovigilance from Patient Safety to Environmental Stewardship.” Her work explores how pharmacovigilance can evolve beyond traditional adverse event reporting and support broader environmental and public health objectives. The abstract introduces a novel “Dual Safety Framework” that connects patient safety with environmental monitoring and reflects the growing importance of the One Health approach within modern pharmacovigilance.

While many pharmacovigilance providers focus primarily on operational execution, participation in international scientific discussions allows Billev Pharma East to remain closely connected to emerging trends, evolving regulations, and future safety expectations. This knowledge directly benefits our clients by helping them anticipate changes before they become compliance challenges.

For Billev Pharma East, participation in international scientific forums is more than a professional achievement. It reflects our commitment to remaining at the forefront of pharmacovigilance, regulatory science, and risk management. By actively contributing to discussions on emerging topics such as radiopharmaceutical safety, environmental stewardship, and future pharmacovigilance frameworks, we help our clients prepare not only for today’s requirements but also for tomorrow’s expectations.

Companies attending ISoP 2026 will have an opportunity to meet the Billev Pharma East team and discuss their pharmacovigilance challenges directly with experts who actively contribute to the global pharmacovigilance community. For organizations considering EU market entry, the event also provides an opportunity to explore European pharmacovigilance requirements, regulatory expectations, and practical strategies for successful expansion into the European market.

Choosing a pharmacovigilance partner for the future

As regulatory expectations continue to evolve, selecting the right pharmacovigilance providers has become a strategic business decision rather than a purely operational one. Pharmaceutical companies need partners who can not only support day-to-day pharmacovigilance activities, but also help navigate emerging regulatory challenges, inspection requirements, scientific developments, and global expansion plans.

The most successful organizations are those that invest in expertise before compliance issues arise. They work with partners who understand the broader regulatory landscape, contribute to the scientific community, and can provide practical guidance when complex safety challenges emerge.

Whether you are evaluating pharmacovigilance providers, preparing for regulatory inspections, strengthening your pharmacovigilance system, or planning entry into the European market, Billev Pharma East offers the expertise, scientific leadership, and practical support needed to achieve long-term compliance with confidence.

Sources: 1 – International Society of Pharmacovigilance (ISoP). (n.d.). What is ISoP?, 2 – International Society of Pharmacovigilance (ISoP). (n.d.). Annual Meetings, 3 – International Society of Pharmacovigilance (ISoP). (2026). ISoP Global Meeting 2026 | San José, Costa Rica | 22–25 September 2026.